With the improved medical technology, cancer patients are exposed to more treatment options than before, and an example of that would be the targeted cancer therapies. And now, add another potential option to that list. The Development Center for Biotechnology has recently developed a new medication, which is proved to be effective in suppressing cancer growth, with limited side effects. The latest drug is going to enter the phase of human clinical trial next year.

Despite continual medical advances, cancer remains the leading cause of death in Taiwan.

More than 10 million people are diagnosed with cancer every year, and targeted therapies are becoming more and more common.

A biotechnology center recently developed a new mTOR targeted therapy that effectively suppresses cancer cells with minimal side effects.

Early tests have shown that the drug is effective against lung cancer, breast cancer, prostate cancer, and lung adenocarcinoma.

The center has received patents for the mTOR suppressant in Taiwan and the United States, and four domestic pharmaceutical companies have formed a research and development alliance to conduct clinical trials for the drug.

Although the biotechnology sector is one of the government's "Two Trillion, Twin Star" industries, little progress has been made.

It costs, on average, US$ 1 billion to bring a new drug to the market, and the success of a drug cannot be predicted.

The development of the drug is currently being funded by the government, while the clinical trials will be privately funded.

According to domestic companies, the biotechnology industry cannot become a "star" industry without the full support of the government.